Johnson & Johnson’s Scientific Response to Combat COVID-19

We are committed to:

- Progress Toward a Vaccine for COVID-19
- Working with partners to screen a library of compounds, and conducting clinical trials to explore potential therapeutics
- Accelerating the clinical development of our SARS-CoV-2 vaccine candidate and expanding our manufacturing and distribution capabilities
- Commitment to Collaboration

Since the early days of the outbreak, Johnson & Johnson has been working with industry partners, governments and health authorities to help end the fast-moving COVID-19 pandemic through the development of a possible preventive vaccine candidate against SARS-CoV-2.

The SARS-CoV-2 vaccine program is leveraging Janssen’s AdVac® technology, which provides the ability to rapidly develop new vaccine candidates.

Vaccine development

- Announcement of our lead vaccine candidate, Ad26.COV2.S, with two backups: March 30, 2020
- Initiation of Phase 1/2a first-in-human clinical trial: July 22, 2020
- Publication of preclinical data in Nature, demonstrating that Ad26.COV2.S protected against infection with SARS-CoV-2: July 30, 2020
- Potential initiation of Phase 3 ENSEMBLE clinical trial: September 2020
- Anticipated availability of first vaccine batch for potential emergency use: Early 2021

Progress Toward a Vaccine for COVID-19

We have been actively engaged in fighting pandemics for over a century. We have done it before, and we will do it again.

Paul Stoffels, M.D.
Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson

Since the early days of the outbreak, Johnson & Johnson has been working with industry partners, governments and health authorities to help end the fast-moving COVID-19 pandemic through the development of a possible preventive vaccine candidate against SARS-CoV-2.

Commitment to Collaboration

The search for a SARS-CoV-2 vaccine and potential COVID-19 treatments is being progressed by partnerships and collaborations, including those between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health & Human Services, and the Biodefense Medical Center (BDMC). We are committed to collaborating with COVID-19 stakeholders to ensure any future effective vaccines and/or therapies against COVID-19 will be accessible wherever needed.

For more information on Johnson & Johnson’s multi-pronged approach to COVID-19, visit jnj.com/coronavirus.